When a new safety issue arises with a medicine, regulators typically publicize advisories so that not just physicians, but also the public is made aware. At least, this is what happens in the U.S. and most European countries — but not in Australia, where researchers found that “unacceptable secrecy” surrounds such warnings and may jeopardize public health.

Unlike regulators elsewhere, the Therapeutics Goods Administration in Australia does not post on its website letters sent to doctors about new drug risks. So the researchers identified 207 drugs from 39 companies for which public warnings about heart failure, seizures, or death were issued in the U.S., the U.K., and Canada between 2007 and 2016, but not in Australia.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy